Chemometec — Marts 2020
-
Despite COVID-19 distractions, competitors within the CAR-T marketplace proliferate
Despite the recent COVID-19 distractions caused by global lock-downs and quarantines worldwide, CAR-T companies are on the rise. The surging number of CAR-T companies have resulted from large investments into CAR-T product development and landmark approvals of CAR-T cell therapies by the U.
(www.linkedin.com)
-
Mesenchymal stem cell (MSC)
Allogeneic MSCs cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia. -
-
-
1
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind